Business
Samsung Epis Holdings Delivers Business Updates at the 44th J.P. Morgan Healthcare Conference
INCHEON, Korea, January 15, 2026--Samsung Epis Holdings shared corporate progress and updates at the 44th J.P. Morgan Healthcare Conference.
About this update from Samsung Epis Holdings Co., Ltd.
[{"type":"image","alt":"Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings","displaySize":"","headline":null,"caption":"Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":420,"url":"https://media.zenfs.com/en/business-wire.com/b1facebe228216e696f145ee4657e618"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/BXU69ktSL2s.IoDvTSlevg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTg0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b1facebe228216e696f145ee4657e618","width":480,"height":420}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":339,"url":"https://media.zenfs.com/en/business-wire.com/5e608702485355c84cdfd11501c0b353"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I8Uety71upGeuOO6Pzngug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY3ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5e608702485355c84cdfd11501c0b353","width":480,"height":339}}},{"type":"list","items":[{"val":[{"type":"text","content":"Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030","length":83,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab, in addition to pembrolizumab currently in Phase 1 and 3 clinical studies","length":200,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Having secured investigational new drug application (IND) clearance from the U.S. Food and Drug Administration (FDA), SBE303, Samsung Bioepis’ novel antibody-drug conjugate (ADC) engineered to target Nectin-4, will enter into the Phase 1 first-in-human clinical trial this year","length":277,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Samsung Bioepis plans to add one novel therapeutic candidate in clinical study every year","length":89,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":649,"olType":false},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"INCHEON, Korea, January 15, 2026--(BUSINESS WIRE)--Samsung Epis Holdings (KRX: 0126Z0) today sh...